Actively Recruiting
Chongqing Primary Aldosteronism Study
Led by Chongqing Medical University · Updated on 2023-09-06
1500
Participants Needed
1
Research Sites
639 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.
CONDITIONS
Official Title
Chongqing Primary Aldosteronism Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hypertensive patients who have completed aldosterone-to-renin ratio (ARR) screening and any necessary further tests
- Willing to voluntarily sign the informed consent form
You will not qualify if you...
- Patients with severe cardiac, liver, or kidney dysfunction
- Patients with suspected or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma, and renal artery stenosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qifu Li
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
Research Team
Q
Qifu Li, phD
CONTACT
S
Shumin Yang, phD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here